Non-alcoholic fatty liver disease
Conditions
Interventions
HLD group:Healthy liver diet intervention
Control group:No changes in diet and physical activity were required.
Sponsors
Danone Dietary Nutrition Research and Education Fund
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1.Chinese Han nationality, aged 18-70 years; 2.Patients with clinically diagnosed NAFLD and liver fat content >= 10% as measured by magnetic resonance imaging proton density fat fraction (MRI-PDFF).
Exclusion criteria
Exclusion criteria: 1.Excessive alcohol intake (30 g/day for men and 20 g/day for women); 2.Patients with severe liver diseases (including chronic active hepatitis B or C, hepatolenticular degeneration, cirrhosis, hepatocellular carcinoma, etc.); 3.Patients with severe organic diseases (cancer, coronary heart disease, myocardial infarction, stroke, renal disease); 4.Autoimmune liver disease (positive antinuclear antibody, anti-smooth muscle antibody, anti-mitochondrial antibody); 5.Taking medications that may cause fatty liver (such as long-term use of steroids, amiodarone, tamoxifen, or methotrexate); 6.Patients who have used drugs that cause liver injury (such as ethamiodarone, antiviral drugs, non-steroidal anti-inflammatory drugs, corticosteroids, methotrexate, tamoxifen, tetracycline, valproic acid, etc.) in the past 3 months; 7.Patients using probiotics in the past 3 months; 8.Severe mental illness; 9.Significant weight loss in the past 6 months; 10.Those unable to undergo MRI due to physical reasons such as claustrophobia or having metal objects in their body; 11.Pregnant, lactating women, and women who intended to become pregnant during the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Liver fat content; | — |
Secondary
| Measure | Time frame |
|---|---|
| Body weight;Waist circumference;Body mass index;Fasting blood glucose;Fasting insulin;Alanine aminotransferase;Aspartate aminotransferase;Glutamyltransferase;Total cholesterol;Triglycerides;High density lipoprotein cholesterol;Low-density lipoprotein cholesterol;Interleukin-6;Tumor necrosis factor;C-reactive protein;Ferritin levels;Leptin;Adiponectin;Fatty acid binding protein 4;Gut Microbiota; | — |
Countries
China
Contacts
Public ContactYanbin Ye
The First Affiliated Hospital of Jinan University
Outcome results
None listed